Cure My Disease

Don't miss your cure!

 Log in / Sign up

Five new drugs aim to tame painful skin condition

NCT ID NCT03827798

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests five different investigational drugs (iscalimab, LYS006, MAS825, remibrutinib, and ianalumab) in 248 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. The main goal is to see if these drugs reduce abscesses and inflammatory nodules by at least 50% without increasing draining tunnels. Participants are randomly assigned to receive a drug or a placebo, and neither they nor their doctors know which they get.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA

Contacts and locations

Locations

  • Advanced Medical Research

    Sandy Springs, Georgia, 30328, United States

  • Dawes Fretzin Clinical Rea Group

    Indianapolis, Indiana, 46256, United States

  • Medical University of South Carolina MUSC

    Charleston, South Carolina, 29425, United States

  • NorthShore University Health System

    Evanston, Illinois, 60201, United States

  • Novartis Investigative Site

    Graz, 8036, Austria

  • Novartis Investigative Site

    Brussels, 1070, Belgium

  • Novartis Investigative Site

    Prague, Prague 1, 11000, Czechia

  • Novartis Investigative Site

    Copenhagen, 2400, Denmark

  • Novartis Investigative Site

    Roskilde, 4000, Denmark

  • Novartis Investigative Site

    Antony, 92160, France

  • Novartis Investigative Site

    Lyon, 69003, France

  • Novartis Investigative Site

    Marseille, 13885, France

  • Novartis Investigative Site

    Nice, 06202, France

  • Novartis Investigative Site

    Reims, 51100, France

  • Novartis Investigative Site

    Rouen, 76031, France

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Frankfurt, 60590, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Schwerin, 19055, Germany

  • Novartis Investigative Site

    Pécs, Baranya, 7623, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    Szeged, H 6725, Hungary

  • Novartis Investigative Site

    Kopavogur, 201, Iceland

  • Novartis Investigative Site

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    Groningen, 9713 GZ, Netherlands

  • Novartis Investigative Site

    Granada, Andalusia, 18014, Spain

  • Novartis Investigative Site

    Sabadell, Barcelona, 08208, Spain

  • Novartis Investigative Site

    Manises, Valencia, 46940, Spain

  • Novartis Investigative Site

    Barcelona, 08041, Spain

  • Novartis Investigative Site

    Las Palmas GC, 35010, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Olympian Clinical Research

    Clearwater, Florida, 33609, United States

  • Park Avenue Dermatology PA

    Orange Park, Florida, 32073, United States

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania, 17033-0850, United States

  • University Of South Florida

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.